MyBCTeam

Yes, Ribociclib (Kisqali) is an oral medication used to treat breast cancer. It belongs to a class of drugs called cyclin-dependent kinase (CDK) 4/6 inhibitors, which work by blocking certain proteins that control cell division. This helps stop breast cancer cells from replicating and growing. Clinical studies have shown Show Full Answer

Yes, Ribociclib (Kisqali) is an oral medication used to treat breast cancer. It belongs to a class of drugs called cyclin-dependent kinase (CDK) 4/6 inhibitors, which work by blocking certain proteins that control cell division. This helps stop breast cancer cells from replicating and growing. Clinical studies have shown impressive results with Ribociclib - 70% of people taking this medication were alive after 42 months of treatment, compared to 46% of those taking hormone therapy alone. It's specifically approved for treating HER2-negative metastatic breast cancer.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Treatments for Metastatic Breast Cancer: Extending Life